Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Artiva Biotherapeutics
Biotech
AACR: New Affimed data disappoints after Nasdaq flags stock dip
Affimed's mid-stage lymphoma treatment has failed to beat standard-of-care treatment, prompting the biotech to pursue a new path for its lead asset.
Gabrielle Masson
Apr 17, 2023 12:52pm
Forte taps new exec amid shareholder dissent—Chutes & Ladders
Jun 10, 2022 9:30am
Merck NK cell ally Artiva splashes out on new digs in San Diego
Aug 12, 2021 9:35am
Artiva, fresh from Merck pact, raises $120M for NK therapy R&D
Feb 26, 2021 9:05am
Merck bags CAR-NKs from Artiva to push into cell therapy
Jan 28, 2021 8:00am
Biopharma targets cancer with next-gen cell therapies
Sep 14, 2020 4:15pm